Japan· JP-1317712Q1033
ピマリシン
A natamycin product containing ピマリシン, registered in Japan by 千寿製薬, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Natamycin is registered in 2 of 19 countries.
Countries holding a registration under ATC A07AA03 (natamycin), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 1 of them publish a price we can compare per daily dose
Natamycin · ATC A07AA03
2 / 19 countries
- Finlandprice
- Japan
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ピマリシン
- Manufacturer
- 千寿製薬
- Country
- Japan (JP)
- ATC code
- A07AA03
- ATC class
- Natamycin
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Natamycin in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPIMAFUCINCHEPLAPHARM Arzneimittel GmbH, Greifswald
- FinlandPimafucinParanova Oy
- PolandPimafucinCHEPLAPHARM Arzneimittel GmbH
- United StatesNATACYNEyevance Pharmaceuticals, LLC
- United KingdomNatacyn 5% ophthalmic suspensionImported (United States)
- NorwayNatacyn
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Czechia · Pimafucin
- Finland · Pimafucin
- Hungary · Pimafucin
- Poland · Pimafucin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/05293323-a9ec-4711-b437-47bd487dc8c7 GET /v1/drugs/05293323-a9ec-4711-b437-47bd487dc8c7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５０ｍｇ１ｍＬ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1317712Q1033",
"category": "外用薬",
"price_yen": 628.3,
"generic_name": "ピマリシン",
"product_name_jp": null,
"therapeutic_class": "1317",
"transitional_expiry": null
}See everything about natamycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.